Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
BIOV | CSE | CAD | Delayed | |
BVAXF | OTC Markets | USD | Delayed | |
5LB | Frankfurt | EUR | Delayed |
BioVaxys Technology Corp., a clinical-stage immunotherapeutic company, engages in developing antiviral and anticancer vaccine platforms. It develops BVX-0320, a SARS-CoV-2 vaccine; BVX-1021, a vaccine for the strain of coronavirus that causes SARS1; and BVX-0918, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, a novel diagnostic platform to identify a T-cell immune response to the presence of SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions. It has a bioproduction agreement with WuXi Biologics Limited to produce SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; and research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320. BioVaxys Technology Corp. is based in Vancouver, Canada.
Name | Age | Since | Title |
---|---|---|---|
Kartik Chandran | - | 2021 | Member of Scientific Advisory Board |
Shmuel Farhi | - | 2021 | Member of Scientific Advisory Board |
Charles J. Dunton | - | 2021 | Member of Advisory Board |
Anthony John Guy Dutton | 67 | 2022 | Independent Director |
Adam Coutts | - | 2021 | Member of Advisory Board |
Yvelise Barrios | - | 2021 | Scientific Adviser |
Craig William Loverock | 53 | 2022 | Independent Director |
James Christopher Passin | 52 | 2016 | Co-Founder, CEO, & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review